🇺🇸 FDA
Patent

US 11260120

Immunogenic composition comprising a fusion peptide derived from superantigen toxoids

granted A61KA61K2039/53A61K2039/55505

Quick answer

US patent 11260120 (Immunogenic composition comprising a fusion peptide derived from superantigen toxoids) held by INTEGRATED BIOTHERAPEUTIC VACCINES, INC. expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
INTEGRATED BIOTHERAPEUTIC VACCINES, INC.
Grant date
Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
44
CPC classes
A61K, A61K2039/53, A61K2039/55505, A61K2039/70, A61K39/085